Neue Therapien für Patienten mit Non-Hodgkin-Lymphomen

Die Einführung einer Vielzahl neuer Therapeutika hat die Behandlungsmöglichkeiten von Patienten mit Non-Hodgkin-Lymphomen (NHL) erheblich erweitert. Insbesondere die Weiterentwicklung zielgerichteter Medikamente wird unsere Therapiekonzepte grundlegend verändern. Anhand von ausgewählten Beispielen gibt dieser Text einen allgemeinen Überblick über aktuelle Therapieoptionen.

Publikationsverlauf

Artikel online veröffentlicht:
11. Mai 2020

• Literatur

• 1 Maloney DG, Grillo-Lopez AJ, Bodkin DJ. et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 3266-3274
• 2 Younes A, Ansell S, Fowler N. et al. The landscape of new drugs in lymphoma. Nat Rev Clin Oncol 2017; 14: 335-346
• 3 Karaman MW, Herrgard S, Treiber DK. et al. quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008; 26: 127-132
• 4 Lancet JE, Uy GL, Cortes JE. et al. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol 2018; 36: 2684-2692
• 5 Rodriguez MA, Durand J, Astrow A. et al. Phase II study of RCHOP with pegylated liposomal doxorubicin (DRCOP) for patients older than age 60 with untreated diffuse large B-cell lymphoma (DLBCL). J Clin Oncol 2011; 29 (Suppl. 15) 8053-8053
• 6 Rummel MJ, Niederle N, Maschmeyer G. et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381: 1203-1210
• 7 Pettengell R, Coiffier B, Narayanan G. et al. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. Lancet Oncol 2012; 13: 696-706
• 8 Pettengell R, Dlugosz-Danecka M, Andorsky D. et al. Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306). Br J Haematol 2020; 188: 240-248
• 9 Robak T, Jin J, Pylypenko H. et al. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. Lancet Oncol 2018; 19: 1449-1458
• 10 Ghobrial IM, Hong F, Padmanabhan S. et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010; 28: 1422-1428
• 11 Seymour JF, Kipps TJ, Eichhorst B. et al. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med 2018; 378: 1107-1120
• 12 Younes A. New drugs for new targets in lymphoma. Hematol Oncol 2019; 37 (Suppl. 01) 105-109
• 13 Friedberg JW, Sharman J, Sweetenham J. et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010; 115: 2578-2585
• 14 Bussel J, Arnold DM, Grossbard E. et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials. Am J Hematol 2018; 93: 921-930
• 15 Jain N, Keating M, Thompson P. et al. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med 2019; 380: 2095-2103
• 16 Wilson WH, Young RM, Schmitz R. et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med 2015; 21: 922-926
• 17 Erdmann T, Klener P, Lynch JT. et al. Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL. Blood 2017; 130: 310-322
• 18 Dreyling M, Santoro A, Mollica L. et al. Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma. J Clin Oncol 2017; 35: 3898-3905
• 19 Rule S, Jurczak W, Jerkeman M. et al. Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. Leukemia 2018; 32: 1799-1803
• 20 Hess G. mTOR inhibition in diffuse large B-cell lymphoma: new hope?. Lancet Haematol 2016; 3: e302-e303
• 21 Sermer D, Pasqualucci L, Wendel HG. et al. Emerging epigenetic-modulating therapies in lymphoma. Nat Rev Clin Oncol 2019; 16: 494-507
• 22 Chapuy B, Stewart C, Dunford A. et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 2018; 24: 679-690
• 23 Pastore A, Jurinovic V, Kridel R. et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol 2015; 16: 1111-1122
• 24 Schmitz R, Wright GW, Huang DW. et al. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med 2018; 378: 1396-1407
• 25 Beguelin W, Popovic R, Teater M. et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 2013; 23: 677-692
• 26 Morschhauser F, Tilly H, Chaidos A. et al. Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma. Blood 2019; 134 (Suppl. 01) 123
• 27 Marcus R, Seymour JF, Hiddemann W. Obinutuzumab Treatment of Follicular Lymphoma. N Engl J Med 2017; 377: 2605-2606
• 28 Sehn LH, Herrera AF, Flowers CR. et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol 2020; 38: 155-165
• 29 Advani R, Flinn I, Popplewell L. et al. CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma. N Engl J Med 2018; 379: 1711-1721
• 30 Ansell SM, Lesokhin AM, Borrello I. et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015; 372: 311-319
• 31 Ramchandren R, Domingo-Domenech E, Rueda A. et al. Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study. J Clin Oncol 2019; 37: 1997-2007
• 32 Zinzani PL, Santoro A, Gritti G. et al. Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study. J Clin Oncol 2019; 37: 3081-3089
• 33 Rosenwald A, Wright G, Leroy K. et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003; 198: 851-862
• 34 Savage KJ, Monti S, Kutok JL. et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003; 102: 3871-3879
• 35 Schuster SJ, Bartlett NL, Assouline S. et al. Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines. Blood 2019; 134 (Suppl. 01) 6
• 36 Locke FL, Ghobadi A, Jacobson CA. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol 2019; 20: 31-42
• 37 Schuster SJ, Bishop MR, Tam CS. et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med 2019; 380: 45-56
• 38 Sehgal AR, Godwin J, Pribble J. et al. Lisocabtagene Maraleucel (liso-cel) for Treatment of Second-Line Transplant Noneligible (TNE) Relapsed/Refractory (R/R) Aggressive Non-Hodgkin Lymphoma (NHL): Initial Results from the PILOT Study. Blood 2019; 134 (Suppl. 01) 2882
• 39 Liu E, Marin D, Banerjee P. et al. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med 2020; 382: 545-553
• 40 Fink EC, Ebert BL. The novel mechanism of lenalidomide activity. Blood 2015; 126: 2366-2369
• 41 Kronke J, Udeshi ND, Narla A. et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 2014; 343: 301-305
• 42 Lu G, Middleton RE, Sun H. et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 2014; 343: 305-309
• 43 Morschhauser F, Fowler NH, Feugier P. et al. Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma. N Engl J Med 2018; 379: 934-947
• 44 Leonard JP, Trneny M, Izutsu K. et al. AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. J Clin Oncol 2019; 37: 1188-1199